Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSPO | P30536 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4841448 | 0.89 | TSPO (0.78) | TSPO | |
| SCHEMBL5746627 | 0.85 | TSPO (0.66) | TSPOSMN1; SMN2POLB | |
| SCHEMBL3920169 | 0.84 | TP53 (0.45) | TSPOSMN1; SMN2POLBKDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL4843306 | 0.84 | TSPO (0.65) | TSPOSMN1; SMN2POLB | |
| SCHEMBL5744887 | 0.83 | TSPO (0.66) | TSPOSMN1; SMN2POLB | |
| Hydrochloric Acid SCHEMBL4842016 | 0.82 | TSPO (0.65) | TSPOSMN1; SMN2POLB | |
| SCHEMBL5786270 | 0.81 | POLB (0.44) | TSPOSMN1; SMN2POLBKDM4EALDH1A1 | |
| SCHEMBL3932062 | 0.80 | ALDH1A1 (0.46) | SMN1; SMN2POLBKDM4EALDH1A1 | |
| SCHEMBL17959431 | 0.79 | TSPO (0.73) | TSPO | |
| SCHEMBL17974080 | 0.79 | TSPO (0.73) | TSPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255129-A1 | 3-Heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino[4,5-b]indole-1-acetamide derivatives, their preparation and their application in therapeutics | SANOFI-AVENTIS (FR) | 2008-10-16 | — | — | US | disclosed |
| US-7405306-B2 | 3-Heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino[4,5-b]indole-1-acetamide derivatives, their preparation and their application in therapeutics | SANOFI-AVENTIS (FR) | 2008-07-29 | — | — | US | disclosed |
| US-20080076775-A1 | 3-Heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino[4,5-b]indole-1-acetamide derivatives, their preparation and their application in therapeutics | SANOFI-AVENTIS (FR) | 2008-03-27 | — | — | US | disclosed |
| US-7323467-B2 | 3-heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino[4,5-b]indole-1-acetamide derivatives, their preparation and their application in therapeutics | SANOFI-AVENTIS (FR) | 2008-01-29 | — | — | US | disclosed |
| US-20070219202-A1 | 3-Heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino[4,5 b]indole-1-acetamide derivatives, their preparation and their application in therapeutics | SANOFI-AVENTIS (FR) | 2007-09-20 | — | — | US | disclosed |
| US-7235554-B2 | 3-heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino[4,5-b] indole-1-acetamide derivatives, preparation and use thereof in medicaments | SANOFI-AVENTIS (FR) | 2007-06-26 | — | — | US | disclosed |
| EP-1492792-B1 | 3-HETEROARYL-3,5-DIHYDRO-4-OXO-4H-PYRIDAZINO¬4,5-B|INDOLE-1-ACETAMIDE DERIVATIVES, PREPARATION AND USE THEREOF IN MEDICAMENTS | SANOFI AVENTIS (FR) | 2006-03-29 | — | — | EP | disclosed |
| US-20050124615-A1 | 3-heteroarly-3,5-dihydro-4-oxo-4h-pyridazino[4,5-b] indole-1-acetamide derivatives, preparation and use thereof in medicaments | SANOFI (FR) | 2005-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076775-A1 | 3-Heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino[4,5-b]indole-1-acetamide derivatives, their preparation and their application in therapeutics | IDO1, IDO2, TPH1 | TSPO 1596/4885SMN1; SMN2 3299/4885POLB 4577/4885 |
| US-20050124615-A1 | 3-heteroarly-3,5-dihydro-4-oxo-4h-pyridazino[4,5-b] indole-1-acetamide derivatives, preparation and use thereof in medicaments | HRH4, IDO1, HTR4 | TSPO 3871/4885SMN1; SMN2 4852/4885POLB 2420/4885 |
| US-20070219202-A1 | 3-Heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino[4,5 b]indole-1-acetamide derivatives, their preparation and their application in therapeutics | IDO1, IDO2, TPH1 | TSPO 1814/4885SMN1; SMN2 3163/4885POLB 4568/4885 |
| US-20080255129-A1 | 3-Heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino[4,5-b]indole-1-acetamide derivatives, their preparation and their application in therapeutics | IDO1, IDO2, TPH1 | TSPO 1596/4885SMN1; SMN2 3299/4885POLB 4577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.